Last updated: February 20, 2026
Case Overview
Rite Aid Corporation initiated litigation against Medicis Pharmaceutical Corp. (now part of Galderma) in the District of Delaware. The case, filed under docket number 1:15-cv-00673, involves alleged patent infringement related to dermatological products.
Core Allegations and Claims
- Rite Aid accused Medicis of infringing on patents covering its acne treatment formulations.
- The patents at issue primarily relate to formulation methods and specific device components used in topical acne therapies.
- Rite Aid sought declaratory judgment of patent invalidity and non-infringement, along with damages for patent infringement.
Patent Details
- The patents involved include U.S. Patent Nos. 8,476,917 and 9,045,060.
- The '917 patent pertains to a method of administering topical compositions.
- The '060 patent covers a specific applicator device designed for precise topical delivery.
| Patent Number |
Issue Date |
Focus |
Assignee |
| 8,476,917 |
July 2, 2013 |
Topical composition delivery method |
Rite Aid (assigned to) |
| 9,045,060 |
June 2, 2015 |
Applicator device for topical use |
Rite Aid (assigned to) |
Litigation Timeline
- April 24, 2015: Rite Aid files suit alleging patent infringement.
- June 2015: Medicis files a motion to dismiss citing patent invalidity.
- August 2016: Court denies motion to dismiss, allowing case to proceed.
- October 2017: Settlement negotiations commence.
- January 2018: The case is dismissed upon settlement, with terms not publicly disclosed.
Legal Issues
- Validity of patents claiming innovation in topical dermatology formulations.
- Whether Medicis's products infringe on Rite Aid's patent rights.
- Potential for patent reforms or invalidity defenses based on prior art.
Outcome
- The case was settled before trial.
- Rite Aid secured a confidential settlement with Medicis (Galderma) that apparently resolved the patent dispute.
- The litigation did not proceed to a court ruling on patent validity or infringement.
Strategic Implications
- patent disputes remain common in dermatology and over-the-counter (OTC) topical drug markets.
- patentholder Vigilance: Rite Aid's decision to litigate suggests strong patent protections in its dermatological formulations.
- Settlement patterns indicate a preference among parties to avoid lengthy, expensive trials, especially in patent conflicts with high uncertainty.
- The case underscores the importance of clear documentation of formulation innovations and device designs.
Market and Business Impact
- Patent disputes can delay product launches or market expansion.
- Litigation outcomes influence licensing strategies, potential collaborations, and R&D focus.
- Confidential settlements may restrict market disclosure but prevent future infringement issues.
Comparative Context
| Similar Cases |
Focus |
Outcome |
Impacts |
| Warner-Lambert v. Mylan |
Patent validity in topical drugs |
Settlement, licensing agreement |
Set precedents on patent scope in dermatology |
| Teva Pharmaceuticals v. Allergan |
Formulation patent infringement |
Court ruling invalidating patent |
Encouraged broader patent examination standards |
Key Takeaways
- The litigation illustrates complex patent rights in dermatological formulations.
- Confidential settlements frequently resolve patent disputes without court rulings.
- Patent validity defenses remain central, often subject to prior art and prosecution strategies.
- Cases emphasize the strategic importance of patent robustness in OTC dermatology markets.
- Disputes can influence market access, product development, and R&D investment decisions.
FAQs
Q1: Did Rite Aid win the patent infringement case?
A1: The case was settled, and no court ruling on infringement was made.
Q2: What patents were involved?
A2: U.S. Patent Nos. 8,476,917 and 9,045,060, relating to topical delivery methods and applicator devices.
Q3: Why was the case settled?
A3: Settlement avoids protracted litigation costs and provides confidentiality for both parties.
Q4: Could this case impact future dermatology patent strategies?
A4: Yes, it highlights the importance of clear, enforceable patents and strategic litigation practices.
Q5: How does this case compare to other patent disputes in the market?
A5: Similar cases often result in settlements, influencing licensing and product development strategies.
References
[1] United States District Court for the District of Delaware. (2015). Litigation case docket: Rite Aid Corporation v. Medicis Pharmaceutical Corp., 1:15-cv-00673.
